Atorvastatin and liraglutide possess lipid-lowering, antioxidant, and anti-inflammatory effects that could synergistically improve obesity-related perturbations through modulation of the Nrf2/HO-1 signaling pathway. This evidence concerns the gene HMOX1 and obesity due to melanocortin 4 receptor deficiency.